studies suggest that APC could be coupled with the only currently approved treatment, tissue plasminogen activator (tPA), to protect the brain from tPA's very harmful side effects, in addition to preventing cell death from lack of oxygen (hypoxia). Clinical use of APC has also been proposed for improving the outcome of pancreatic islet transplantation in treating type I diabetes. Ceprotin was approved for medical used in the European Union in July 2001. Ceprotin is indicated in purpura fulminans and coumarin-induced skin necrosis in people with severe congenital protein C deficiency. See also Activated protein C–protein C inhibitor Notes References External links The MEROPS online database for peptidases and their inhibitors: S01.218 Coagulation system Peripheral membrane proteins EC 3.4.21 Angiology Hematology Zymogens